Merkx, R.I.J.; Rijpkema, M.; Franssen, G.M.; Kip, A.; Smeets, B.; Morgenstern, A.; Bruchertseifer, F.; Yan, E.; Wheatcroft, M.P.; Oosterwijk, E.;
et al. Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model. Pharmaceuticals 2022, 15, 570.
https://doi.org/10.3390/ph15050570
AMA Style
Merkx RIJ, Rijpkema M, Franssen GM, Kip A, Smeets B, Morgenstern A, Bruchertseifer F, Yan E, Wheatcroft MP, Oosterwijk E,
et al. Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model. Pharmaceuticals. 2022; 15(5):570.
https://doi.org/10.3390/ph15050570
Chicago/Turabian Style
Merkx, Robin I. J., Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk,
and et al. 2022. "Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model" Pharmaceuticals 15, no. 5: 570.
https://doi.org/10.3390/ph15050570
APA Style
Merkx, R. I. J., Rijpkema, M., Franssen, G. M., Kip, A., Smeets, B., Morgenstern, A., Bruchertseifer, F., Yan, E., Wheatcroft, M. P., Oosterwijk, E., Mulders, P. F. A., & Heskamp, S.
(2022). Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model. Pharmaceuticals, 15(5), 570.
https://doi.org/10.3390/ph15050570